Press release
Antisense and RNAi Therapeutics Market to Witness a Pronounce Growth by 2023
The rising incidence of coronary artery diseases, cardiac ailments, and neurodegenerative and infectious diseases has led to the demand for antisense and RNai therapeutics. The market exhibits a strong pipeline of product and is looking forward to introduce several advancements in the RNAi drug delivery technology. These factors will act as high growth rendering drivers in the coming years.
Browse through Antisense and RNAi Therapeutics Market report to know what factors will shape the market by 2023: http://www.transparencymarketresearch.com/antisense-rnai-therapeutics-market.html
The global antisense and RNAi therapeutics market is still at a nascent stage, however, will product approvals on cards, the market is forecast to report strong growth between 2015 and 2023. Market players are expecting lucrative prospects as collaborations between RNA licensing therapeutic developers and pharmaceutical giants gain pace.
The report provides a comprehensive analysis of the global antisense and RNAi therapeutics market covering present product portfolio and those in pipeline. Factors influencing the market’s trajectory over the forecast period are studied in detail. Information included in the report is obtained via trusted industrial sources and substantiated using decisive data. Information comprised in the report is thus intended to help stakeholders gain a better perspective of the global antisense and RNAi therapeutics market.
Global Antisense and RNAi Therapeutics Market: Trends and Opportunities
Besides collaborations between therapeutic developments and pharmaceutical companies, alliances are taking place between operating entities and outsourcing partners. These alliances have allowed operating entities outsource research and licensing activities to third-party partners while focusing on their core competencies. These recent trends, as per industry veterans, hold strong growth potential for the overall market.
Moreover, the discovery of ribonucleic acid silencing has paved avenues for treatments, which are developed using interference mechanism of RNA. However, the market is yet to pick desired pace, as complexities with regards to delivering target molecules to target organs continue to haunt scientists and drug developers. Nevertheless, with the advent of novel nano-technology oriented techniques, which exhibited higher efficacy in target delivery, has enabled the industry exhibit positive trajectory. Also with the implementation of favorable government initiatives and as a result of external funding, the global antisense and RNAi therapeutics market will exhibit strong growth in the coming years.
Global Antisense and RNAi Therapeutics Market: Regional Outlook
The global antisense and RNAi therapeutics market can be broadly classified under North America, Latin America, Europe, the Middle East & Africa, and Asia Pacific based on region. Of these, North America has showcased the most lucrative opportunities in the past and has thus contributed a considerable share to the overall industry. The region boasts a rising number clinical trials and government policies therein support the process of initiation for developing antisense therapeutics. Besides this, a large number of clinical laboratories are engaged in research and development activities in the field, which has warranted significant growth to the North America market in the coming years. It is important to note here, that clinical laboratories in North America also contribute to revenue generation via product and platform licensing. The potential commercialization of a few candidates under research and development will help the antisense and RNAi therapeutics market to pick up pace in North America in the near future.
However, in the period post commercialization of these therapies, opportunities in Asia Pacific are expected to get more lucrative, exhibiting a higher growth rate. The rising government spending toward research and development in topical, besides other forms of siRNA delivery techniques is a strong factor aiding the market’s trajectory in Asia Pacific.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving Antisense and RNAi Therapeutics Market by 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4949
Global Antisense and RNAi Therapeutics Market: Vendor Landscape
Isis Pharmaceuticals, Alnylam Pharmaceuticals, Silence Therapeutics, Antisense Therapeutics, Santaris, and miRagen Therapeutics are some of the leading players in the global antisense and RNAi therapeutics market. To gain a stronger foothold, these companies are majorly focusing on strategic collaborations and licensing deals.
Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Antisense and RNAi Therapeutics Market to Witness a Pronounce Growth by 2023 here
News-ID: 570351 • Views: …
More Releases from TMR - Research Reports
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during…
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the…
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016.
The global dental membrane and bone graft substitutes market is expected to…
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period.
By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment…
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand.
Browse 156 Market Data Tables and 112 Figures spread through 175…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited.
Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring…
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year.
Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved…
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018!
Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led…
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion.
One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and…
